Gresser I, Maury C, Carnaud C, De Maeyer E, Maunoury M T, Belardelli F
Institut de Recherches Scientifiques sur le Cancer, C.N.R.S., Villejuif, Paris, France.
Int J Cancer. 1990 Sep 15;46(3):468-74. doi: 10.1002/ijc.2910460324.
DBA/2 mice were injected i.v. with IFN alpha/beta-resistant 3CI8 Friend erythroleukemia cells (FLC) which metastasize to the liver and spleen. IFN alpha/beta treatment of FLC-injected mice increased their survival time and these mice developed a resistance to a second challenge with FLC. The efficacy of IFN alpha/beta in increasing the survival time was compared between normal immunocompetent and immunodeficient mice. The anti-tumor action of IFN was markedly reduced or abolished in newborn DBA/2 mice, in adult athymic nu/nu and beige DBA/2 mice, and in BALB/c scid/scid mice. To determine the phenotype of the effector cells involved, FLC-injected DBA/2 mice were treated with antibodies to asialo-GMI, CD4, or CD8 antigens, or with cyclosporin A or silica. IFN alpha/beta treatment proved much less effective in these mice, indicating that a variety of effector cell types participated in the IFN-induced suppression of visceral metastases. Thus, an intact immune system appears to be essential to obtain optimal therapeutic effects of IFN alpha/beta in this experimental model.
给DBA/2小鼠静脉注射对α/β干扰素耐药的3CI8弗氏红白血病细胞(FLC),这些细胞会转移至肝脏和脾脏。对注射了FLC的小鼠进行α/β干扰素治疗可延长其存活时间,并且这些小鼠对再次接种FLC产生了抗性。比较了正常免疫活性小鼠和免疫缺陷小鼠中α/β干扰素在延长存活时间方面的疗效。在新生DBA/2小鼠、成年无胸腺裸鼠和米色DBA/2小鼠以及BALB/c scid/scid小鼠中,干扰素的抗肿瘤作用明显降低或消失。为了确定所涉及的效应细胞的表型,给注射了FLC的DBA/2小鼠用抗脱唾液酸GM1、CD4或CD8抗原的抗体,或用环孢菌素A或二氧化硅进行处理。在这些小鼠中,α/β干扰素治疗的效果要差得多,这表明多种效应细胞类型参与了干扰素诱导的对内脏转移的抑制作用。因此,在这个实验模型中,完整的免疫系统似乎是获得α/β干扰素最佳治疗效果所必需的。